Apollo Endosurgery Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery or view top-rated stocks.

Wall Street analysts have given Apollo Endosurgery a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Apollo Endosurgery wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Apollo Endosurgery saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 206,700 shares, an increase of 116.2% from the April 29th total of 95,600 shares. Based on an average daily volume of 846,200 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.4% of the company's shares are short sold.
View Apollo Endosurgery's Short Interest.

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Apollo Endosurgery.

Apollo Endosurgery, Inc. (NASDAQ:APEN) released its earnings results on Monday, May, 3rd. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.05. The biotechnology company had revenue of $13.86 million for the quarter, compared to the consensus estimate of $11.78 million. Apollo Endosurgery had a negative net margin of 37.52% and a negative trailing twelve-month return on equity of 730.71%.
View Apollo Endosurgery's earnings history.

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has increased by 320.8% and is now trading at $8.69.
View which stocks have been most impacted by COVID-19.

2 brokers have issued 1-year target prices for Apollo Endosurgery's stock. Their forecasts range from $11.00 to $12.00. On average, they anticipate Apollo Endosurgery's stock price to reach $11.50 in the next year. This suggests a possible upside of 32.3% from the stock's current price.
View analysts' price targets for Apollo Endosurgery or view top-rated stocks among Wall Street analysts.

Some companies that are related to Apollo Endosurgery include Orthofix Medical (OFIX), Surmodics (SRDX), Asensus Surgical (ASXC), Antares Pharma (ATRS), SeaSpine (SPNE), Invo Bioscience (IVOB), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Vapotherm (VAPO), PAVmed (PAVM), AVITA Medical (RCEL), Intersect ENT (XENT), Soliton (SOLY), Pulse Biosciences (PLSE) and Acutus Medical (AFIB).
View all of APEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery's stock is owned by a number of institutional and retail investors. Top institutional shareholders include CPMG Inc (11.72%), Nantahala Capital Management LLC (8.43%), Gagnon Securities LLC (5.80%), Goldman Sachs Group Inc. (2.38%), Renaissance Technologies LLC (1.50%) and Manatuck Hill Partners LLC (0.93%). Company insiders that own Apollo Endosurgery stock include David Pacitti, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends for Apollo Endosurgery.

APEN stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, and Nantahala Capital Management LLC.
View insider buying and selling activity for Apollo Endosurgery or view top insider-selling stocks.

APEN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Manatuck Hill Partners LLC, Gagnon Securities LLC, Parkman Healthcare Partners LLC, Millennium Management LLC, CPMG Inc, Neuberger Berman Group LLC, and Geode Capital Management LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include John R Barr, Neil Gagnon, and R Kent Mcgaughy Jr.
View insider buying and selling activity for Apollo Endosurgery or or view top insider-buying stocks.

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APEN stock can currently be purchased for approximately $8.69.

Apollo Endosurgery has a market capitalization of $234.94 million and generates $42.05 million in revenue each year. The biotechnology company earns $-22,610,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

Apollo Endosurgery employs 158 workers across the globe.

The official website for Apollo Endosurgery is www.apolloendo.com.

Apollo Endosurgery is headquartered at 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]